Cargando…

Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy

Background: Fabry disease (FD) is characterized by early development of vasculopathy and endothelial dysfunction. However, it is unclear whether these findings also play a pivotal role in cardiac manifestation. As Fabry cardiomyopathy (FC) is the leading cause of death in FD, we aimed to gather a be...

Descripción completa

Detalles Bibliográficos
Autores principales: Loso, Jefferson, Lund, Natalie, Avanesov, Maxim, Muschol, Nicole, Lezius, Susanne, Cordts, Kathrin, Schwedhelm, Edzard, Patten, Monica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104487/
https://www.ncbi.nlm.nih.gov/pubmed/30159316
http://dx.doi.org/10.3389/fcvm.2018.00108
_version_ 1783349498171359232
author Loso, Jefferson
Lund, Natalie
Avanesov, Maxim
Muschol, Nicole
Lezius, Susanne
Cordts, Kathrin
Schwedhelm, Edzard
Patten, Monica
author_facet Loso, Jefferson
Lund, Natalie
Avanesov, Maxim
Muschol, Nicole
Lezius, Susanne
Cordts, Kathrin
Schwedhelm, Edzard
Patten, Monica
author_sort Loso, Jefferson
collection PubMed
description Background: Fabry disease (FD) is characterized by early development of vasculopathy and endothelial dysfunction. However, it is unclear whether these findings also play a pivotal role in cardiac manifestation. As Fabry cardiomyopathy (FC) is the leading cause of death in FD, we aimed to gather a better insight in pathological mechanisms of the disease. Methods: Serum samples were obtained from 17 healthy controls, 15 FD patients with and 7 without FC. FC was defined by LV wall thickening of >12 mm in cardiac magnetic resonance imaging and serum level of proBNP, high sensitive Troponin T (hsT), and globotriaosylsphingosine (lyso-GB3) were obtained. A multiplex ELISA-Assay for 23 different angiogenesis markers was performed in pooled samples. Markers showing significant differences among groups were further analyzed in single samples using specific Elisa antibody assays. L-homoarginine (hArg), L-arginine, asymmetric (ADMA), and symmetric Dimethylarginine (SDMA) were quantified by liquid chromatography—mass spectrometry. Results: Angiostatin and matrix metalloproteinase 9 (MMP-9) were elevated in FD patients compared to controls independently of the presence of FC (angiostatin: 98 ± 25 vs. 75 ± 15 ng/mL; p = 0.001; MMP-9: 8.0 ± 3.4 vs. 5.0 ± 2.4 μg/mL; p = 0.002). SDMA concentrations were highest in patients with FC (0.90 ± 0.64 μmol/l) compared to patients without (0.57 ± 0.10 μmol/l; p = 0.027) and vs. controls (0.58 ± 0.12 μmol/l; p = 0.006) and was positively correlated with indexed LV-mass (r = 0.61; p = 0.003), hsT (r = 0.56, p = 0.008), and lyso-Gb3 (r = 0.53, p = 0.013). Accordingly, the ratio of L-homoarginine to SDMA (hArg/SDMA) was lowest in patients with FC (2.63 ± 1.78) compared to controls (4.16 ± 1.44; p = 0.005). For L-arginine, hArg and ADMA no significant differences among groups could be detected, although a trend toward higher ADMA and lower hArg levels could be observed in the FC group. Furthermore, a significant relationship between kidney and cardiac function could be revealed (p = 0.045). Conclusion: Elevated MMP-9 and angiostatin levels suggest an increased extracellular matrix turnover in FD patients. Furthermore, endothelial dysfunction may also be involved in FC, as SDMA and hArg/SDMA are altered in these patients.
format Online
Article
Text
id pubmed-6104487
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61044872018-08-29 Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy Loso, Jefferson Lund, Natalie Avanesov, Maxim Muschol, Nicole Lezius, Susanne Cordts, Kathrin Schwedhelm, Edzard Patten, Monica Front Cardiovasc Med Cardiovascular Medicine Background: Fabry disease (FD) is characterized by early development of vasculopathy and endothelial dysfunction. However, it is unclear whether these findings also play a pivotal role in cardiac manifestation. As Fabry cardiomyopathy (FC) is the leading cause of death in FD, we aimed to gather a better insight in pathological mechanisms of the disease. Methods: Serum samples were obtained from 17 healthy controls, 15 FD patients with and 7 without FC. FC was defined by LV wall thickening of >12 mm in cardiac magnetic resonance imaging and serum level of proBNP, high sensitive Troponin T (hsT), and globotriaosylsphingosine (lyso-GB3) were obtained. A multiplex ELISA-Assay for 23 different angiogenesis markers was performed in pooled samples. Markers showing significant differences among groups were further analyzed in single samples using specific Elisa antibody assays. L-homoarginine (hArg), L-arginine, asymmetric (ADMA), and symmetric Dimethylarginine (SDMA) were quantified by liquid chromatography—mass spectrometry. Results: Angiostatin and matrix metalloproteinase 9 (MMP-9) were elevated in FD patients compared to controls independently of the presence of FC (angiostatin: 98 ± 25 vs. 75 ± 15 ng/mL; p = 0.001; MMP-9: 8.0 ± 3.4 vs. 5.0 ± 2.4 μg/mL; p = 0.002). SDMA concentrations were highest in patients with FC (0.90 ± 0.64 μmol/l) compared to patients without (0.57 ± 0.10 μmol/l; p = 0.027) and vs. controls (0.58 ± 0.12 μmol/l; p = 0.006) and was positively correlated with indexed LV-mass (r = 0.61; p = 0.003), hsT (r = 0.56, p = 0.008), and lyso-Gb3 (r = 0.53, p = 0.013). Accordingly, the ratio of L-homoarginine to SDMA (hArg/SDMA) was lowest in patients with FC (2.63 ± 1.78) compared to controls (4.16 ± 1.44; p = 0.005). For L-arginine, hArg and ADMA no significant differences among groups could be detected, although a trend toward higher ADMA and lower hArg levels could be observed in the FC group. Furthermore, a significant relationship between kidney and cardiac function could be revealed (p = 0.045). Conclusion: Elevated MMP-9 and angiostatin levels suggest an increased extracellular matrix turnover in FD patients. Furthermore, endothelial dysfunction may also be involved in FC, as SDMA and hArg/SDMA are altered in these patients. Frontiers Media S.A. 2018-08-15 /pmc/articles/PMC6104487/ /pubmed/30159316 http://dx.doi.org/10.3389/fcvm.2018.00108 Text en Copyright © 2018 Loso, Lund, Avanesov, Muschol, Lezius, Cordts, Schwedhelm and Patten. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Loso, Jefferson
Lund, Natalie
Avanesov, Maxim
Muschol, Nicole
Lezius, Susanne
Cordts, Kathrin
Schwedhelm, Edzard
Patten, Monica
Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
title Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
title_full Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
title_fullStr Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
title_full_unstemmed Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
title_short Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
title_sort serum biomarkers of endothelial dysfunction in fabry associated cardiomyopathy
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104487/
https://www.ncbi.nlm.nih.gov/pubmed/30159316
http://dx.doi.org/10.3389/fcvm.2018.00108
work_keys_str_mv AT losojefferson serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy
AT lundnatalie serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy
AT avanesovmaxim serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy
AT muscholnicole serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy
AT leziussusanne serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy
AT cordtskathrin serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy
AT schwedhelmedzard serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy
AT pattenmonica serumbiomarkersofendothelialdysfunctioninfabryassociatedcardiomyopathy